Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion

被引：0
|
作者：
Akinobu Kurita
Shoichi Kado
Norimasa Kaneda
Masaharu Onoue
Shusuke Hashimoto
Teruo Yokokura
机构：
[1] Yakult Central Institute for Microbiological Research,
来源：
Cancer Chemotherapy and Pharmacology | 2003年 / 52卷
关键词：
Irinotecan hydrochloride; CPT-11; SN-38; Myelosuppression; Acute diarrhea; Delayed-onset diarrhea;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：349 / 360
页数：11
相关论文
共 50 条
  • [41] NONLINEAR PHARMACOKINETICS OF CPT-11 IN RATS
    KANEDA, N
    YOKOKURA, T
    CANCER RESEARCH, 1990, 50 (06) : 1721 - 1725
  • [42] Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408
    Fujishiro, M
    Shinkai, T
    Fukuda, M
    Tamura, T
    Ohe, Y
    Kunitoh, H
    Nishiwaki, Y
    Sekine, I
    Fukuda, H
    Saijo, N
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2000, 30 (11) : 487 - 493
  • [43] Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11)
    Chen, Shujuan
    Yueh, Mei-Fei
    Bigo, Cyril
    Barbier, Olivier
    Wang, Kepeng
    Karin, Michael
    Nghia Nguyen
    Tukey, Robert H.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (47) : 19143 - 19148
  • [44] Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction
    Ong, SYK
    Clarke, SJ
    Bishop, J
    Dodds, HM
    Rivory, LP
    ANTI-CANCER DRUGS, 2001, 12 (07) : 619 - 625
  • [45] Irinotecan (CPT-11) in the elderly: our experience on feasibility and toxicity
    Capello, C
    Milanesi, E
    Evangelisti, L
    Ferraris, C
    Granello, M
    Bellinato, C
    Ferrero, DM
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 226 - 226
  • [46] Pharmacology of Topoisomerase I Inhibitors Irinotecan (CPT-11) and Topotecan
    Mathijssen, Ron H. J.
    Loos, Walter J.
    Verweij, Jaap
    Sparreboom, Alex
    CURRENT CANCER DRUG TARGETS, 2002, 2 (02) : 103 - 123
  • [47] Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: The European perspective
    Bleiberg, H
    Cvitkovic, E
    EUROPEAN JOURNAL OF CANCER, 1996, 32A : S18 - S23
  • [48] Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11)
    Palmer, RD
    Williams, DM
    MEDICAL AND PEDIATRIC ONCOLOGY, 2003, 41 (01): : 78 - 80
  • [49] Irinotecan (CPT-11) in pretreated metastatic colorectal cancer (CRC)
    Lara, MA
    Feliu, J
    Salinas, P
    Fernandez, Y
    Garcia-Giron, C
    ANNALS OF ONCOLOGY, 1998, 9 : 45 - 46
  • [50] A Pharmacokinetic Study of Irinotecan (CPT-11) During Inflammation in Mice
    Chityala, Pavan Kumar
    Wu, Lei
    Taneja, Guncha
    Chow, Diana
    Hu, Ming
    Gao, Song
    Ghose, Romi
    FASEB JOURNAL, 2018, 32 (01):
12345